New biopsy test could predict chemo success in breast cancer
NCT ID NCT03524430
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a new lab test called the RNA Disruption Assay (RDA) to see if it can tell how well breast cancer is responding to chemotherapy. Researchers will take small tissue samples (biopsies) from the tumor at specific times during treatment and analyze them. The goal is to see if the test results match up with whether the tumor completely disappears after treatment. About 800 women with early-stage breast cancer are taking part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could give doctors a way to tell early on whether chemotherapy is working for a breast cancer patient, allowing them to switch treatments sooner if needed.
What could go wrong
This is an observational study, not a treatment trial. The test is still being validated and may not reliably predict outcomes for all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INVASIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital U. 12 de Octubre
Madrid, Spain
-
Institut de Cancerologie de Strasbourg
Strasbourg, France
-
NZOZ Neuromed
Lublin, Poland
-
SST di Cremona Multidisciplinare di Patologia Mammaria, Italy
Cremona, Italy
-
Siteman Cancer Center
St Louis, Missouri, 63129, United States
-
Sunnybrook Health Sciences Center
Toronto, Canada
-
Universitätsklinikum Münster
Münster, Germany